Theravance Biopharma Inc

TBPH

Healthcare|Biotechnology|USA

$16.94

-0.06 (-0.32%)

Tangible Book

$5.64

Graham Number

$11.62

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Trials past primary completion date but still active — data readout may be imminent.

Jan 2026

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy